JPMorgan ETFS Ireland ICAV (JGNR) News

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form D - Notice of Exempt Offering of Securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

--Announces Reorganization of Board of Directors-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain...